Amarin Corporation(US:AMRN) Globenewswire·2025-11-03 13:30Core Insights - Amarin Corporation will present new findings at the American Heart Association's Scientific Sessions 2025, reinforcing the efficacy of VASCEPA®/VAZKEPA® in cardiovascular risk reduction and highlighting the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA) [1][2] Group 1: Study Findings - New analyses from the REDUCE-IT study will evaluate the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular outcomes with or without baseline use of aspirin [2] - Mechanistic studies will explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] and its anti-inflammatory and endothelial-protective properties [2] Group 2: Presentation Details - Featured abstracts will be presented by academic collaborators, including a session on the efficacy of Icosapent Ethyl for cardiovascular risk reduction by aspirin use in REDUCE-IT [7] - Additional presentations will cover the effects of EPA on endothelial cells during inflammation and its impact on lipoprotein oxidation [5][8] Group 3: Company Overview - Amarin is a global pharmaceutical company focused on reducing the cardiovascular disease burden and advancing cardiovascular care, with a direct sales approach in the U.S. and an indirect distribution strategy internationally [5] - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising icosapent ethyl, launched in January 2020 for high-risk patients with persistent cardiovascular risk [6][9]